17. Dooley WC, Ljung BM, Veronesi U, Cazzaniga M, Elledge RM, O’Shaughnessy JA, Kuerer HM, Hung DT, Khan SA, Phillips RF, Ganz PA, Euhus DM, Esserman LJ, Haffty BG, King BL, Kelley MC, Anderson MM, Schmit PJ, Clark RR, Kass FC, Anderson BO, Troyan SL, Arias RD, Quiring JN, Love SM, Page DL, King EB. 2001. Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. J Natl Cancer Inst 93(21):1624-1632.

18. Duffy MJ. 2001. Clinical uses of tumor markers: a critical review. Crit Rev Clin Lab Sci 38(3):225-262.

19. Esserman L, Wolverton D, Hylton N. 2002. Magnetic resonance imaging for primary breast cancer management: current role and new applications. Endocr Relat Cancer 9(2):141-153.

20. Esserman LJ. 2002. New approaches to the imaging, diagnosis, and biopsy of breast lesions. Cancer J 8(Suppl 1):S1-S14.

21. Evron E, Dooley WC, Umbricht CB, Rosenthal D, Sacchi N, Gabrielson E, Soito AB, Hung DT, Ljung B, Davidson NE, Sukumar S. 2001. Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet 357(9265):1335-1336.

22. Fabian CJ, Kamel S, Zalles C, Kimler BF. 1996. Identification of a chemoprevention cohort from a population of women at high risk for breast cancer. J Cell Biochem Suppl 25:112-122.

23. Flacke S, Fischer S, Scott MJ, Fuhrhop RJ, Allen JS, McLean M, Winter P, Sicard GA, Gaffney PJ, Wickline SA, Lanza GM. 2001. Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques. Circulation 104(11):1280-1285.

24. Garber K. 2004. Genomic medicine. Gene expression tests foretell breast cancer’s future. Science 303(5665):1754-1755.

25. Gruvberger S, Ringner M, Chen Y, Panavally S, Saal LH, Borg A, Ferno M, Peterson C, Meltzer PS. 2001. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 61(16):5979-5984.

26. Hollon T. 2002. Classifying breast cancer models. The Scientist 16(17):20-24.

27. Institute of Medicine. 2001. Mammography and Beyond: Developing Technologies for the Early Detection of Breast Cancer. Washington, DC: National Academy Press.

28. Jeffrey SS, Pollack JR. 2003. The diagnosis and management of pre-invasive breast disease: promise of new technologies in understanding pre-invasive breast lesions. Breast Cancer Res 5(6):320-328.

29. Josephson L, Kircher MF, Mahmood U, Tang Y, Weissleder R. 2002. Near-infrared fluorescent nanoparticles as combined MR/optical imaging probes. Bioconjug Chem 13(3):554-560.

30. Kallioniemi A. 2002. Molecular signatures of breast cancer—predicting the future. N Engl J Med 347(25):2067-2068.

31. Kang HW, Josephson L, Petrovsky A, Weissleder R, Bogdanov A Jr. 2002. Magnetic resonance imaging of inducible E-selectin expression in human endothelial cell culture. Bioconjug Chem 13(1):122-127.

32. Kuo WP, Jenssen TK, Butte AJ, Ohno-Machado L, Kohane IS. 2002. Analysis of matched mRNA measurements from two different microarray technologies. Bioinformatics 18(3):405-412.

33. Lakhani SR, Ashworth A. 2001. Microarray and histopathological analysis of tumours: the future and the past? Nat Rev Cancer 1(2):151-157.

34. Lanza GM, Wickline SA. 2001. Targeted ultrasonic contrast agents for molecular imaging and therapy. Prog Cardiovasc Dis 44(1):13-31.

35. Lewis R. 2002. Breast cancer: the big picture emerges. The Scientist 17(3):24-25.

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement